Global US drug manufacturers MSD are to invest €40m in their Biotechnology facility at Kilsheelan House, Ballydine, Clonmel, Co. Tipperary this year; installing new technology which it intends to use to further improve a number of its products.
The MSD plant has been in operation for over 40 years, and currently exports to some 30 countries, including destinations in Europe, Japan and the USA.
The site at Ballydine, Co Tipperary, which currently employs 600 people, (some 1,800 people employed by the company in Ireland), develops and supplies the active ingredients for a range of its medical products.
This promised investment brings MSD’s total investment; spent over a three-year period, to €75m, in upgrading this Tipperary facility.
The new technology to be installed, under the current €40m investment promised, includes a spray drying facility, which is used in the production of a number of new products; increasing their solubility and improving how they are absorbed into the human body by patients.
Mr Ger Carmody, Associate Vice President, and Plant Manager at MSD Ballydine, has stated that this current investment truly reflects the growing importance of MSD in Ireland and its overall operations in the group’s global network.
Leave a Reply